Oncopeptides ABFRA:OND +0.35%30 PS Ratio is 4.84 as of Jul. 04, 2026, which is 61% below its 10-year median of 12.53. GuruFocus rates FRA:OND with a GF Score™ of 30/100 and a GF Value™ of €0.37 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 933 Biotechnology companies, Oncopeptides AB ranks better than 66.35% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Oncopeptides AB's share price is €0.1453.
Oncopeptides AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €0.03. Hence, Oncopeptides AB's PS Ratio for today is 4.84.
The historical rank and industry rank for Oncopeptides AB's PS Ratio or its related term are showing as below:
FRA:OND'
s PS Ratio Range Over the Past 10 Years
Min: 2.06 Med: 12.53 Max: 533.13
Current: 5.13
During the past 12 years, Oncopeptides AB's highest PS Ratio was 533.13. The lowest was 2.06. And the median was 12.53.
FRA:OND's PS Ratio is ranked better than 66.35% of 933
companies
in the Biotechnology industry
Industry Median: 9.64
vs FRA:OND: 5.13
During the past 12 months, the average Revenue per Share Growth Rate of Oncopeptides AB was 69.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 66.60% per year.
During the past 12 years, Oncopeptides AB's highest 3-Year average Revenue per Share Growth Rate was 66.60% per year. The lowest was -43.60% per year. And the median was 11.50% per year.
Back to Basics: PS Ratio
Oncopeptides AB (FRA:OND) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Oncopeptides AB PS Ratio Related Terms
Oncopeptides AB PS Ratio Historical Data
* Premium members only.
The historical data trend for Oncopeptides AB's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Oncopeptides AB's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncopeptides AB PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oncopeptides AB's PS Ratio distribution charts can be found below:
* The bar in red indicates where Oncopeptides AB's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Oncopeptides AB's Share Price of today is €0.1453. Oncopeptides AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.03.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Oncopeptides AB (FRA:OND) has a PS Ratio of 4.84 as of Jul. 04, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Oncopeptides AB and its competitors. This is 61% below median its historical median of 12.53. Over the past decade, Oncopeptides AB's PS Ratio has ranged from 2.06 to 533.13. According to the industry distribution chart, Oncopeptides AB ranks #314 out of 933 companies in the Biotechnology industry, placing it in the top 33.7%.
Is Oncopeptides AB's PS Ratio too high?
Oncopeptides AB's current PS Ratio of 4.84 is 61% below median its 10-year median of 12.53. Over the past 10 years, this metric has ranged from a low of 2.06 to a high of 533.13. The Biotechnology industry median PS Ratio is 9.64. Oncopeptides AB's value of 4.84 is 49.8% below this industry median. Based on the distribution chart, Oncopeptides AB ranks #314 out of 933 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Oncopeptides AB has a GF Score™ of 30/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Oncopeptides AB's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oncopeptides AB ranks #314 out of 933 companies for PS Ratio. This puts Oncopeptides AB in the upper half of its industry. The industry median PS Ratio is 9.64. Oncopeptides AB's value of 4.84 is 49.8% below this benchmark. Historically, Oncopeptides AB's own PS Ratio has ranged from 2.06 to 533.13 over the past decade. While the company's 10-year median is 12.53 vs. the industry median of 9.64, Oncopeptides AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.64, based on 933 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oncopeptides AB's current PS Ratio of 4.84 is 49.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Oncopeptides AB and its competitors. For the Biotechnology industry, the median PS Ratio is 9.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oncopeptides AB's current PS Ratio is 4.84, which is 61% below median its own 10-year median of 12.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncopeptides AB stock overvalued right now?
Based on GuruFocus' analysis, Oncopeptides AB (FRA:OND) is currently considered Possible Value Trap. The stock's GF Value™ is €0.37, compared to a current price of €0.15 — trading 60.7% below its estimated fair value. The current PS Ratio is 4.84, which is 61% below median its 10-year median of 12.53 and 49.8% below the Biotechnology industry median of 9.64. Oncopeptides AB's overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Oncopeptides AB (FRA:OND), the current PS Ratio is 4.84 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncopeptides AB (FRA:OND) Overvalued in 2026?
Based on GuruFocus' analysis, Oncopeptides AB stock appears to be undervalued.
The current stock price of €0.15 is trading 60.7% below its estimated GF Value™ of €0.37.
GuruFocus considers Oncopeptides AB to be Possible Value Trap.
Key valuation signals for FRA:OND:
PS Ratio: 4.84 (61% below median its 10-year median of 12.53)
GF Value™: €0.37 vs. price of €0.15 (60.7% below fair value)
Industry Position: 49.8% below the Biotechnology median (#314 of 933)
No single metric tells the full story. See the FRA:OND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncopeptides AB is a Swedish biotech company focusing on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company uses its proprietary Peptide Drug Conjugate platform to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It is a science-driven biotech company developing targeted therapies for hard-to-treat cancers, combining cutting-edge research, entrepreneurial spirit, and a deep commitment to improving patients' lives. Its flagship drug is currently being commercialized in Europe with partnership agreements for South Korea, the Middle East, Africa, and elsewhere. The company generates maximum revenue from Germany.
30GF Score
Get the complete analysis for FRA:OND
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:OND has been successfully added to your 
